New Research Highlights Potential of iOnctura Strategy Combining Autotaxin and TGF-Β Inhibitors In Cancer
Amsterdam, The Netherlands and Geneva, Switzerland, 19 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces publication of new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.